Trial watch: BTK inhibitor shows positive results in B cell malignancies.
作者： Charlotte Harrison
DOI: 10.1038/NRD3656
关键词: Clinical trial 、 Bruton's tyrosine kinase 、 B cell 、 Immunology 、 B-cell lymphoma 、 Tyrosine kinase 、 Hematology 、 Internal medicine 、 Medicine
摘要: Preliminary clinical trial data recently presented at the American Society of Hematology meeting showed that Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 was effective in treating several types B cell lymphoma. Furthermore, is centre a deal — worth up to US$975 million between drug's developer Pharmacyclics and Janssen Biotech.
nature.com
sci-hub.se 参考文章(0)